CSPIA
VERV

Cary Street Partners Investment Advisory’s Verve Therapeutics VERV Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,000
Closed -$13.3K – 1747
2023
Q3 		$13.3K Hold
1,000
– – ﹤0.01% 1222
2023
Q2 		$18.8K Sell
1,000
-300
-23% -$5K ﹤0.01% 1064
2023
Q1 		$18.7K Hold
1,300
– – ﹤0.01% 995
2022
Q4 		$25.2K Buy
+1,300
New +$34.4K ﹤0.01% 913

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Cary Street Partners Investment Advisory's VERV Position: Q4 2023 in Review

Cary Street Partners Investment Advisory sold out of Verve Therapeutics (VERV) in Q4 2023, closing a stake of 1,000 shares — an estimated $13.3K sold.

Cary Street Partners Investment Advisory first reported a position in VERV in Q4 2022 and held it in 4 quarters. The position peaked at $25.2K in Q4 2022. 157 funds tracked by Wall St. Rank hold VERV as of Q4 2023.

  • Cary Street Partners Investment Advisory reported no remaining Verve Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Cary Street Partners Investment Advisory sold 1,000 Verve Therapeutics shares in Q4 2023, an estimated $13.3K.
  • Cary Street Partners Investment Advisory first reported a position in Verve Therapeutics in Q4 2022 and held it in 4 quarters.
  • Cary Street Partners Investment Advisory's Verve Therapeutics position peaked at $25.2K in Q4 2022.
  • 157 funds tracked by Wall St. Rank held Verve Therapeutics as of Q4 2023.

Based on Cary Street Partners Investment Advisory's 13F filing for Q4 2023, filed 5 Feb 2024.